Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy
详细信息    查看全文
  • 作者：Kenji Ishikura (1)
    Shinsuke Matsumoto (2)
    Mayumi Sako (3)
    Kazushi Tsuruga (4)
    Koichi Nakanishi (5)
    Koichi Kamei (6)
    Hiroshi Saito (7)
    Shuichiro Fujinaga (8)
    Yuko Hamasaki (9)
    Hiroko Chikamoto (10)
    Yasufumi Ohtsuka (11)
    Yasuhiro Komatsu (12)
    Toshiyuki Ohta (13)
    Takuhito Nagai (14)
    Hiroshi Kaito (15)
    Shuji Kondo (16)
    Yohei Ikezumi (17)
    Seiji Tanaka (18)
    Yoshitsugu Kaku (19)
    Kazumoto Iijima (20)

    1. Department of Nephrology     ; Tokyo Metropolitan Children鈥檚 Medical Center ; 2-8-29 Musashidai ; Fuchu ; Tokyo ; 183-8561 ; Japan
    2. Department of Pediatrics     ; Matsudo City Hospital Children鈥檚 Medical Center ; Chiba ; Japan
    3. Division for Clinical Trials     ; Department of Development Strategy ; Center for Social and Clinical Research ; National Research Institute for Child Health and Development ; Tokyo ; Japan
    4. Department of Pediatrics     ; Hirosaki University Graduate School of Medicine ; Hirosaki ; Japan
    5. Department of Pediatrics     ; Wakayama Medical University ; Wakayama ; Japan
    6. Department of Nephrology and Rheumatology     ; National Center for Child Health and Development ; Tokyo ; Japan
    7. Department of Pediatrics     ; Nihon University School of Medicine ; Tokyo ; Japan
    8. Division of Nephrology     ; Saitama Children鈥檚 Medical Center ; Saitama ; Japan
    9. Department of Pediatric Nephrology     ; Toho University Faculty of Medicine ; Tokyo ; Japan
    10. Department of Pediatric Nephrology     ; School of Medicine ; Tokyo Women鈥檚 Medical University ; Tokyo ; Japan
    11. Department of Pediatrics     ; Faculty of Medicine ; Saga University ; Saga ; Japan
    12. Division of Nephrology     ; Department of Medicine ; St. Luke鈥檚 International Hospital ; Tokyo ; Japan
    13. Department of Pediatric Nephrology     ; Hiroshima Prefectural Hospital ; Hiroshima ; Japan
    14. Department of Nephrology     ; Aichi Children鈥檚 Health and Medical Center ; Aichi ; Japan
    15. Department of Pediatrics     ; Kobe University Graduate School of Medicine ; Kobe ; Japan
    16. Department of Pediatrics     ; Institute of Health Bioscience ; Tokushima University ; Tokushima ; Japan
    17. Department of Pediatrics     ; Niigata University Medical and Dental Hospital ; Niigata ; Japan
    18. Department of Pediatrics and Child Health     ; Kurume University Medical Center ; Fukuoka ; Japan
    19. Department of Nephrology     ; Fukuoka Children鈥檚 Hospital ; Fukuoka ; Japan
    20. Department of Pediatrics     ; Kobe University Graduate School of Medicine ; Kobe ; Japan
  • 刊名：Clinical and Experimental Nephrology
  • 出版年：2015
  • 出版时间：February 2015
  • 年：2015
  • 卷：19
  • 期：1
  • 页码：6-33
  • 全文大小：783 KB
  • 参考文献：1. Schlesinger ER, Sultz HA, Mosher WE, Feldman JG. The nephrotic syndrome. Its incidence and implications for the community. Am J Dis Child. 1968;116:623鈥?2.
    2. Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Arch Dis Child. 1982;57:544鈥?.
    3. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 1997;8:769鈥?6.
    4. Arbeitsgemeinschaft f眉r P盲diatrische Nephrologie. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med. 1982;306:451鈥?
    5. Fukui T, Yoshida M, Yamaguchi N. Minds Handbook for Guideline Development 2007. Tokyo: IGAKU-SHOIN Ltd.; 2007 (article in Japanese).
    6. Lohr KN. Clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press. Field MJ; 1990.
    7. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. 1981;98:561鈥?.
    8. International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13:159鈥?5
    9. Gulati S, Sharma AP, Sharma RK, Gupta A, Gupta RK. Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? Pediatr Nephrol. 2002;17:404鈥?.
    10. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis. 1998;32:72鈥?.
    11. Kim JH, Park SJ, Yoon SJ, Lim BJ, Jeong HJ, Lee JS, Kim PK, Shin JI. Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome. J Clin Pathol. 2011;64:516鈥?.
    12. Kengne-Wafo S, Massella L, Diomedi-Camassei F, Gianviti A, Vivarelli M, Greco M, Stringini GR, Emma F. Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol. 2009;4:1409鈥?6.
    13. Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 2002;61:1801鈥?.
    14. Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child. 2006;91:666鈥?0.
    15. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, Nakanishi K, Yata N, Honda M. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73:1167鈥?3.
    16. Ishikura K, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Yata N, Ando T, Honda M, for Japanese Study Group of Renal Disease in Children. Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome. Nephrol Dial Transplant. 2010;25:3956鈥?2.
    17. Morgan C, Sis B, Pinsk M, Yiu V. Renal interstitial fibrosis in children treated with FK506 for nephrotic syndrome. Nephrol Dial Transplant. 2011;26:2860鈥?.
    18. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of 鈥淎rbeitsgemeinschaft f眉r P盲diatrische Nephrologie鈥? Lancet. 1979;1:401鈥?.
    19. Ueda N, Chihara M, Kawaguchi S, Niinomi Y, Nonoda T, Matsumoto J, Ohnishi M, Yasaki T. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr. 1988;112:122鈥?.
    20. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft for Pediatrische Nephrologie. Eur J Pediatr. 1993;152:357鈥?1.
    21. Ksiazek J, Wyszy艅ska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr. 1995;84:889鈥?3.
    22. Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol. 1999;13:824鈥?.
    23. Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M. West Japan Cooperative Study Group of Kidney Disease in Children. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis. 2003;41:1155鈥?2.
    24. Norero C, Delucchi A, Lagos E, Rosati P. Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18聽months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children. Rev Med Chil. 1996;124:567鈥?2 (article in Spanish).
    25. Yoshikawa N, Ito H, Takekoshi Y, Honda M, Awazu M, Iijima K, Nakamura H, Seino Y, Takeda N, Hattori S, Matsuda I. Standard versus long-term prednisolone with Sairei-to for initial therapy in childhood steroid-responsive nephrotic syndrome: a prospective controlled study. Jpn J Nephrol. 1998;40:587鈥?0 (article in Japanese).
    26. Lande MB, Gullion C, Hogg RJ, Gauthier B, Shah B, Leonard MB, Bonilla-Felix M, Nash M, Roy S 3rd, Strife CF, Arbus G. Long versus standard initial steroid therapy for children with the nephrotic syndromeA report from the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 2003;18:342鈥?.
    27. Hirano D, Nishizaki N, Kanai H, Hara S, Ohtomo Y, Umino D, Fujinaga S. Long-term outcome of children treated with the ISKDC regimen for the first episode of INS. Jpn J Nephrol. 2010;52:1029鈥?6 (article in Japanese).
    28. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2007;(4):CD001533.
    29. Ekka BK, Bagga A, Srivastava RN. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol. 1997;11(5):597鈥?.
    30. Hoyer PF, Brodeh J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol. 2006;17:1151鈥?.
    31. Hayashi M, Kimura N, Fukatsu A. Combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome: comparison with prednisolone therapy. Jpn J Nephrol. 2008;50:581鈥? (article in Japanese).
    32. Yoshikawa N, Ito H. Kampo medicine for pediatric renal disease: nephrotic syndrome. J Tradit Sino-Jpn Med. 1991;12:24鈥? (article in Japanese).
    33. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. 2008;(1):CD002290.
    34. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant. 1993;8:1326鈥?2.
    35. Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol. 1991;35 Suppl1:S31鈥?.
    36. El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, Taha N, Hassan N, Sayed-Ahmad N, Sobh M. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant. 2005;20:2433鈥?.
    37. Kitano Y, Yoshikawa N, Tanaka R, Nakamura H, Ninomiya M, Ito H. Ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1990;4(5):474鈥?.
    38. Tanaka R, Yoshikawa N, Kitano Y, Ito H, Nakamura H. Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1993;7:249鈥?2.
    39. Inoue Y, Iijima K, Nakamura H, Yoshikawa N. Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1999;13(1):33鈥?.
    40. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ito S, Yata N, Ando T, Honda M. Japanese Study Group of Renal Disease in Children. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin J Am Soc Nephrol. 2012;7:1576鈥?3.
    41. Kemper MJ, Kuwertz-Broeking E, Bulla M, Mueller-Wiefel DE, Neuhaus TJ. Recurrence of severe steroid dependency in cyclosporin A-treated childhood idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2004;19:1136鈥?1.
    42. Niaudet P, Reigneau O, Humbert H. A pharmacokinetic study of Neoral in childhood steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2001;16:154鈥?.
    43. David-Neto E, Araujo LM, Brito ZM, Alves CF, Lemos FC, Yagyu EM, Nahas WC, Ianhez LE. Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve. Am J Transplant. 2002;2:546鈥?0.
    44. Filler G. How should microemulsified cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored. Nephrol Dial Transplant. 2005;20:1032鈥?.
    45. Suzuki K, Oki E, Tsuruga K, Aizawa-Yashiro T, Ito E, Tanaka H. Benefits of once-daily administration of cyclosporine a for children with steroid-dependent, relapsing nephrotic syndrome. Tohoku J Exp Med. 2010;220:183鈥?.
    46. Fujinaga S, Hirano D, Murakami H, Ohtomo Y, Shimizu T, Kaneko K. Nephrotoxicity of once-daily cyclosporine A in minimal change nephrotic syndrome. Pediatr Nephrol. 2012;27:671鈥?.
    47. Barratt TM, Soothill JF. Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet. 1970;2:479鈥?2.
    48. International Study of Kidney Disease in Children (ISKDC). Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet. 1974;2:423鈥?.
    49. Barratt TM, Cameron JS, Chantler C, Ogg CS, Soothill JF. Comparative trial of 2聽weeks and 8聽weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Arch Dis Child. 1973;48:286鈥?0.
    50. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12聽week course. Report of Arbeitsgemeinschaft f眉r P盲diatrische Nephrologie. Arch Dis Child 1987;62:1102鈥?.
    51. Ueda N, Kuno K, Ito S. Eight and 12聽week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child. 1990;65:1147鈥?0.
    52. Kyrieleis HA, Levtchenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis. 2007;49:592鈥?.
    53. Cammas B, Harambat J, Bertholet-Thomas A, Bouissou F, Morin D, Guigonis V, Bendeddouche S, Afroukh-Hacini N, Cochat P, Llanas B, Decramer S, Ranchin B. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2011;26:178鈥?4.
    54. Vester U, Kranz B, Zimmermann S, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol. 2003;18:661鈥?.
    55. Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, Loirat C, Desch锚nes G, Baudouin V. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:927鈥?2.
    56. Srivastava RN, Agarwal RK, Choudhry VP, Moudgil A, Bhuyan UN, Sunderam KR. Cyclophosphamide therapy in frequently relapsing nephrotic syndrome with and without steroid dependence. Int J Pediatr Nephrol. 1985;6:245鈥?0.
    57. Zagury A, de Oliveira AL, de Moraes CA, de Araujo Montalv茫o JA, Novaes RH, de S谩 VM, Monteiro de Carvalho Dde B, Matuck T. Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:915鈥?0.
    58. Garin EH, Pryor ND, Fennell RS 3rd, Richard GA. Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy. J Pediatr. 1978;92:304鈥?.
    59. Kemper MJ, Altrogge H, Ludwig K, Timmermann K, M眉ller-Wiefel DE. Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2000;14:772鈥?.
    60. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001;16:271鈥?2.
    61. Siegel NJ, Gaudio KM, Krassner LS, McDonald BM, Anderson FP, Kashgarian M. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int. 1981;19:454鈥?.
    62. Tejani A, Phadke K, Nicastri A, Adamson O, Chen CK, Trachtman H, Tejani C. Efficacy of cyclophosphamide in steroid-sensitive childhood nephrotic syndrome with different morphological lesions. Nephron. 1985;41:170鈥?.
    63. Gulati S, Pokhariyal S, Sharma RK, Elhence R, Kher V, Pandey CM, Gupta A. Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome. Nephrol Dial Transplant. 2001;16:2013鈥?.
    64. Bircan Z, Kara B. Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome. Pediatr Int. 2003;45:65鈥?.
    65. Prasad N, Gulati S, Sharma RK, Singh U, Ahmed M. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2004;19:494鈥?.
    66. Donia AF, Gazareen SH, Ahmed HA, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA. Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children. Nephrol Dial Transplant. 2003;18:2054鈥?.
    67. Wetzels JF. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis. Neth J Med. 2004;62:347鈥?2.
    68. Hodson EM, Craig JC, Willis NS. Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2005;20:1523鈥?0.
    69. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259:2123鈥?.
    70. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58:317鈥?4.
    71. Kawasaki Y, Hosoya M, Kobayashi S, Ohara S, Onishi N, Takahashi A, Isome M, Suzuki H. Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome. Nephrol Dial Transplant. 2005;20(10):2243鈥?.
    72. Kawasaki Y, Takano K, Isome M, Suzuki J, Suyama K, Kanno H, Fujiki T, Suzuki H, Hosoya M. Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome. J Nephrol. 2007;20:52鈥?.
    73. Fujieda M, Ishihara M, Morita T, Hayashi A, Utsunomiya Y, Ohta T, Sakano T, Wakiguchi H. Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol. 2008;69:179鈥?4.
    74. Ohtomo Y, Fujinaga S, Takada M, Murakami H, Akashi S, Shimizu T, Kaneko K, Yamashiro Y. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol. 2005;20:1744鈥?.
    75. Fujinaga S, Hirano D, Nishizaki N, Someya T, Ohtomo Y, Ohtsuka Y, Shimizu T, Kaneko K. Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol. 2011;26:479鈥?3.
    76. Goto M, Ikeda M, Hataya H, Ishikura K, Hamasaki Y, Honda M. Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome. Jpn J Nephrol. 2006;48:365鈥?0 (article in Japanese).
    77. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269鈥?9.
    78. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321鈥?.
    79. Prytu艂a A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25:461鈥?.
    80. Sellier-Leclerc AL, Macher MA, Loirat C, Gu茅rin V, Watier H, Peuchmaur M, Baudouin V, Desch锚nes G. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109鈥?5.
    81. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5:2207鈥?2.
    82. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T. Kaneko K.ingle infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25:539鈥?4.
    83. Sinha A, Bagga A, Gulati A, Hari P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2012;27:235鈥?1.
    84. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:1308鈥?5.
    85. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, D枚tsch J. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27:1910鈥?.
    86. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Gu茅rin V, Lapillonne H, Desch锚nes G, Ulinski T. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood鈥揻ollow-up after CD19 recovery. Nephrol Dial Transplant. 2012;27:1083鈥?.
    87. Hiramoto R, Matsumoto S, Eguchi H, Miyoshi Y, Komori I, Akikusa B, Shibata S, Kamei K. Iijima K A case of a 7-year-old boy with steroid-dependent nephrotic syndrome who developed severe neutropenia three months after the administration of rituximab. Japanese Journal of Pediatric Nephrology. 2009;22:97鈥?01 (article in Japanese).
    88. Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol. 2013;28:145鈥?
    89. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187鈥?8.
    90. Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Desch锚nes G. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009;24:1753鈥?.
    91. Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, Tse SM, Benseler SM. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126:e243鈥?.
    92. Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis. 2003;42:1114鈥?0.
    93. Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006;1:1173鈥?.
    94. Afzal K, Bagga A, Menon S, Hari P, Jordan SC. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2007;22:2059鈥?5.
    95. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol. 2003;18:833鈥?.
    96. Ulinski T, Dubourg L, Sa茂d MH, Parchoux B, Ranchin B, Cochat P. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol. 2005;20:482鈥?.
    97. Mendiz谩bal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol. 2005;20:914鈥?.
    98. Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T. Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int. 2007;49:933鈥?.
    99. Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol. 2007;22:71鈥?.
    100. Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol. 2009;72:268鈥?3.
    101. Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol. 2004;19:101鈥?.
    102. Dorresteijn EM. Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol. 2008;23:2013鈥?0.
    103. Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2005;20:1265鈥?.
    104. Al-Akash S, Al-Makdama A. Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Ann Saudi Med. 2005;25:380鈥?.
    105. Baudouin V, Alberti C, Lapeyraque AL, Bensman A, Andr茅 JL, Broux F, Cailliez M, Decramer S, Niaudet P, Desch锚nes G, Jacqz-Aigrain E, Loirat C. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol. 2012;27:389鈥?6.
    106. Dittrich K, Knerr I, Rascher W, D枚tsch J. Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment. Pediatr Nephrol. 2006;21:958鈥?1.
    107. Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant. 2006;21:1848鈥?4.
    108. D枚tsch J, Dittrich K, Plank C, Rascher W. Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A. Nephrol Dial Transplant. 2006;21:1761鈥?.
    109. Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant. 2007;22:2183鈥?3.
    110. Mori K, Honda M, Ikeda M. Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:1232鈥?.
    111. Hamasaki Y, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Yata N, Kaneko T, Honda M. Japanese Study Group of Renal Disease. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24:2177鈥?5.
    112. Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:45鈥?0.
    113. Karle SM, Uetz B, Ronner V, Glaeser L, Hildebrandt F, Fuchshuber A. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2002;13:388鈥?3.
    114. Weber S, Gribouval O, Esquivel EL, Morini猫re V, T锚te MJ, Legendre C, Niaudet P, Antignac C. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 2004;66:571鈥?.
    115. Chernin G, Heeringa SF, Gbadegesin R, Liu J, Hinkes BG, Vlangos CN, Vega-Warner V, Hildebrandt F. Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2008;23:1455鈥?0.
    116. Sant铆n S, Bullich G, Taz贸n-Vega B, Garc铆a-Maset R, Gim茅nez I, Silva I, Ru铆z P, Ballar铆n J, Torra R, Ars E. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2011;6:1139鈥?8.
    117. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, Pasquali S, Castellani A, Della Casa Alberighi O. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43:1377鈥?4.
    118. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996;7:56鈥?3.
    119. Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009;53:760鈥?.
    120. Mahmoud I, Basuni F, Sabry A, El-Husseini A, Hassan N, Ahmad NS, Elbaz M, Moustafa F, Sobh M. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2005;20:735鈥?2.
    121. Hamasaki Y, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Ito S, Kaneko T, Honda M, for Japanese Study Group of Renal Disease in Children. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol. 2013;28:765鈥?1.
    122. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol. 1995;5:1820鈥?.
    123. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56:2220鈥?.
    124. Heering P, Braun N, M眉llejans R, Ivens K, Z盲uner I, F眉nfst眉ck R, Keller F, Kr盲mer BK, Schollmeyer P, Risler T, Grabensee B. German Collaborative Glomerulonephritis Study Group Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis. 2004;43:10鈥?.
    125. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. 1994;125:981鈥?.
    126. Sako M, Iijima K, Saito M, Ohashi Y, Yoshikawa N. Cyclosporine C2 monitaring for frequently relapsing nephrotic syndrome in children: a randomized controlled trial. Jpn J Nephrol. 2012;54:253 (article in Japanese).
    127. Naito M, Takei T, Eguchi A, Uchida K, Tsuchiya K, Nitta K. Monitoring of blood cyclosporine concentration in steroid-resistant nephrotic syndrome. Intern Med. 2008;47:1567鈥?2.
    128. Ishikura K, Ikeda M, Hamasaki Y, Hataya H, Nishimura G, Hiramoto R, Honda M. Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. Nephrol Dial Transplant. 2008;23:2531鈥?536.
    129. Segarra A, Vila J, Pou L, Maj贸 J, Arb贸s A, Quiles T, Piera LL. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant. 2002;17:655鈥?2.
    130. Waldo FB, Benfield MR, Kohaut EC. Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone. Pediatr Nephrol. 1998;12:397鈥?00.
    131. Yorgin PD, Krasher J, Al-Uzri AY. Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2001;16:245鈥?0.
    132. Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol. 2010;25:899鈥?03.
    133. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996;10:590鈥?.
    134. Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W. Arbeits-gemeinschaft f眉r P盲diatrische Nephrologie. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft f眉r P盲diatrische Nephrologie. Pediatr Nephrol. 2008;23:1483鈥?3.
    135. Yi Z, Li Z, Wu XC, He QN, Dang XQ, He XJ. Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol. 2006;21:967鈥?2.
    136. Paik KH, Lee BH, Cho HY, Kang HG, Ha IS, Cheong HI, Jin DK, Moon KC, Choi Y. Primary focal segmental glomerular sclerosis in children: clinical course and prognosis. Pediatr Nephrol. 2007;22:389鈥?5.
    137. Troyanov S. Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16:1061鈥?.
    138. Martinelli R, Okumura AS, Pereira LJ, Rocha H. Primary focal segmental glomerulosclerosis in children: prognostic factors. Pediatr Nephrol. 2001;16:658鈥?1.
    139. Abeyagunawardena AS, Sebire NJ, Risdon RA, Dillon MJ, Rees L, Van鈥檛 Hoff W, Kumarasiri PV, Trompeter RS. Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol. 2007;22:215鈥?1.
    140. Crenshaw G, Bigler S, Salem M, Crook ED. Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors. Am J Med Sci. 2000;319:320鈥?.
    141. Stiles KP, Abbott KC, Welch PG, Yuan CM. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol. 2001;56:89鈥?5.
    142. Muso E, Mune M, Yorioka N, Nishizawa Y, Hirano T, Hattori M, Sugiyama S, Watanabe T, Kimura K, Yokoyama H, Sato H, Saito T. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol. 2007;67:341鈥?.
    143. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y; Kansai FGS, LDL Apheresis Treatment (K-FLAT) Study Group. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron. 2001;89:408鈥?5.
    144. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y, Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kidney Int Suppl. 1999;71:122鈥?.
    145. Tojo K, Sakai S, Miyahara T. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Nihon Jinzo Gakkai Shi. 1988;30:1153鈥?0.
    146. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis. 2003;42:1121鈥?0.
    147. Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol. 1998;50:1鈥?.
    148. Okada T, Takahashi H, Ogura M, Nakao T, Shimizu T. Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment. Jpn J Nephrol. 1996;38:46鈥?1 (article IN Japanese).
    149. Franke D, Zimmering M, Wolfish N, Ehrich JH, Filler G. Treatment of FSGS with plasma exchange and immunadsorption. Pediatr Nephrol. 2000;14:965鈥?.
    150. Feld SM, Figueroa P, Savin V, Nast CC, Sharma R, Sharma M, Hirschberg R, Adler SG. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis. 1998;32:230鈥?.
    151. Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant. 1998;13:1524鈥?.
    152. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol. 2012;23:1117鈥?4.
    153. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:281鈥?.
    154. Bhimma R, Adhikari M, Asharam K, Connolly C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol. 2006;26:544鈥?1.
    155. Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant. 2008;23:910鈥?.
    156. Butani L, Ramsamooj R. Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24:1517鈥?3.
    157. Roberti I, Vyas S. Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol. 2010;25:1117鈥?4.
    158. Pandirikkal VB, Jain M, Gulati S. Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome. Pediatr Nephrol. 2007;22:298鈥?00.
    159. de Mello VR, Rodrigues MT, Mastrocinque TH, Martins SP, de Andrade OV, Guidoni EB, Scheffer DK, Martini Filho D, Toporovski J, Benini V. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol. 2010;25:453鈥?0.
    160. Li Z, Duan C, He J, Wu T, Xun M, Zhang Y, Yin Y. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2010;25:883鈥?.
    161. Gargah TT, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol. 2011;24:203鈥?.
    162. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D鈥橝gati VD, Friedman AL. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80:868鈥?8.
    163. Kyrieleis HA, L枚wik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF, Levtchenko EN. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 2009;4:1593鈥?00.
    164. Requi茫o-Moura LR, Veras de S Freitas T, Franco MF, Pereira AB, Mastroianni-Kirsztajn G. Should adolescents with glomerulopathies be treated as children or adults? Nephron Clin Pract. 2008;109:c161鈥?.
    165. Simmonds J, Grundy N, Trompeter R, Tullus K. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child. 2010;95:146鈥?.
    166. Emma F, Sesto A, Rizzoni G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2003;18:783鈥?.
    167. Takahashi T, Inaba S, Oshima T, Ishihara S, Toyoda Y, Kurose K, Takai R, Yoshida A, Okada T, Takada T, Yanagihara T. Growth of children with idiopathic nephrotic syndrome. The effect of steroid therapy. J Jpn Pediatr Soc. 1991;95:1850鈥? (article in Japanese).
    168. Kaku Y, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ishikura K, Iijima K. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy, clinical and experimental nephrology. Clin Exp Nephrol. doi:10.1007/s10157-014-1031-9 .
    169. Kranz B, Vester U, B眉scher R, Wingen AM, Hoyer PF. Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol. 2008;23:581鈥?.
    170. Drube J, Geerlings C, Taylor R, Mengel M, Ehrich JH. Fifteen-year remission of a steroid-resistant nephrotic syndrome sustained by cyclosporine A. Pediatr Nephrol. 2007;22:600鈥?.
    171. Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A, Sanna-Cherchi S, Emma F, Allegri L, Cancarini G, Rizzoni GF, Perfumo F. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther. 2004;26:1411鈥?.
    172. Chishti AS, Sorof JM, Brewer ED, Kale AS. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis. 2001;38:754鈥?0.
    173. Hino S, Takemura T, Okada M, Murakami K, Yagi K, Fukushima K, Yoshioka K. Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis. 1998;31:932鈥?.
    174. Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol. 1996;7:543鈥?.
    175. Neuhaus TJ, Burger HR, Klingler M, Fanconi A, Leumann EP. Long-term low-dose cyclosporin A in steroid dependent nephrotic syndrome of childhood. Eur J Pediatr. 1992;151:775鈥?.
    176. Melocoton TL, Kamil ES, Cohen AH, Fine RN. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis. 1991;18:583鈥?.
    177. Fujinaga S, Ohtomo Y, Akashi S, Kaneko K. Chronic cyclosporine-induced nephropathy in children with nephrotic syndrome. Japanese Journal of Pediatric Nephrology. 2004;17:66鈥?1 (article in Japanese).
    178. Bogdanovi膰 R, Bani膰evi膰 M, Cvori膰 A. Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study. Pediatr Nephrol. 1990;4:451鈥?.
    179. Jones DP, Stapleton FB, Roy S 3rd, Wyatt RJ. Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome. Pediatr Nephrol. 1988;2:291鈥?.
  • 刊物类别：Medicine
  • 刊物主题：Medicine & Public Health
    Nephrology
    Internal Medicine
    Urology and Andrology
  • 出版者：Springer Japan
  • ISSN：1437-7799
文摘

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700